A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
Status:
Recruiting
Trial end date:
2023-08-23
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of GSK3511294 (Depemokimab) as an adjunctive
therapy in participants with severe uncontrolled asthma with an eosinophilic phenotype
despite standard of care (SoC) treatment with medium to high dose inhaled corticosteroid
(ICS) plus at least one additional controller.